Demirezen A, Faruk AÖ, Helvaci Ö, Derici U, Yıldız Ş, Akyürek N

Idioma: Ingles.
Referencias bibliográficas: 17
Paginas: 38-42
Archivo PDF: 250.83 Kb.

RESUMEN

El trastorno linfoproliferativo postrasplante suele manifestarse en el primer año tras el trasplante de órganos sólidos, aunque raramente puede aparecer después de diez años. El linfoma de Burkitt postrasplante es infrecuente y agresivo. Su tratamiento incluye la reducción de inmunosupresores, rituximab y quimioterapia. Presentamos un caso raro de linfoma de Burkitt que se presentó 18 años después de un trasplante renal. Tras el diagnóstico, el paciente fue tratado con everolimus, rituximab y quimioterapia, logrando una remisión completa, que se ha mantenido durante siete años sin tratamiento adicional. Este caso resalta la posibilidad de aparición tardía de estos trastornos, subrayando la importancia de una vigilancia a largo plazo. Además, el uso de sirolimus/everolimus combinado con rituximab y quimioterapia puede asegurar una respuesta completa y sostenida en el linfoma de Burkitt postrasplante.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Ergisi M, Ooi B, Salim O, Papalois V. Post-transplantlymphoproliferative disorders following kidneytransplantation: A literature review with updates onrisk factors, prognostic indices, screening strategies,treatment and analysis of donor type. Transplant Rev(Orlando). 2024 Apr;38(2):100837.

2. Francis A, Johnson DW, Teixeira-Pinto A, CraigJC, Wong G. Incidence and predictors of posttransplantlymphoproliferative disease after kidneytransplantation during adulthood and childhood: aregistry study. Nephrol Dial Transplant. 2018 May1;33(5):881-889

3. Dharnidharka VR, Webster AC, Martínez OM,Preiksaitis JK, Leblond V, Choquet S. Post-transplantlymphoproliferative disorders. Nat Rev Dis Primers.2016 Jan 28;2:15088.

4. Atallah-Yunes SA, Salman O, Robertson MJ. Posttransplantlymphoproliferative disorder: Update ontreatment and novel therapies. Br J Haematol. 2023May;201(3):383-395.

5. Walczak P, Choquet S, Dantal J, Boutboul D, SuarezF, Baron M et al. Post-transplantation Burkittlymphoma: a retrospective study of 55 patients.Hematológica. 2023 Oct 1;108(10):2814-2819. https://doi.org/10.3324/haematol.2022.282297

6. Picarsic J, Jaffe R, Mazariegos G, Webber SA,Ellis D, Green MD et al. Post-transplant Burkittlymphoma is a more aggressive and distinct formof post-transplant lymphoproliferative disorder.Cancer. 2011 Oct 1;117(19):4540-50. https://doi.org/10.1002/cncr.26001

7. Zimmermann H, Reinke P, Neuhaus R, LehmkuhlH, Oertel S, Atta J et al. Burkitt post-transplantationlymphoma in adult solid organ transplant recipients:sequential immunochemotherapy with rituximab(R) followed by cyclophosphamide, doxorubicin,vincristine, and prednisone (CHOP) or R-CHOP issafe and effective in an analysis of 8 patients. Cancer.2012 Oct 1;118(19):4715-24. https://doi.org/10.1002/cncr.27482

8. DeStefano CB, Desai SH, Shenoy AG, Catlett JP.Management of post-transplant lymphoproliferativedisorders. Br J Haematol. 2018 Aug;182(3):330-343.

9. Allen UD, Preiksaitis JK. AST InfectiousDiseases Community of Practice. Post-transplantlymphoproliferative disorders, Epstein-Barr virusinfection, and disease in solid organ transplantation:Guidelines from the American Society ofTransplantation Infectious Diseases Community ofPractice. Clin Transplant. 2019 Sep;33(9):e13652.

10. Dharnidharka VR, Ruzinova MB, Marks LJ. Post-Transplant Lymphoproliferative Disorders. SeminNephrol. 2024 Jan;44(1):151503.

11. Luskin MR, Heil DS, Tan KS, Choi S, StadtmauerEA, Schuster SJ et al. The Impact of EBV Status onCharacteristics and Outcomes of Post-transplantationLymphoproliferative Disorder. Am J Transplant.2015 Oct;15(10):2665-73.

12. Ferreiro JF, Morscio J, Dierickx D, VandenbergheP, Gheysens O, Verhoef G et al. EBV-Positiveand EBV-Negative Posttransplant Diffuse LargeB Cell Lymphomas Have Distinct Genomic andTranscriptomic Features. Am J Transplant. 2016Feb;16(2):414-25.

13. Nieto-Ríos JF, Gómez de Los Ríos SM, Serna-Higuita LM, Ocampo-Kohn C, Aristizábal-AlzateA, Gálvez-Cárdenas KM et al. Treatment of posttransplantationlymphoproliferative disorders afterkidney transplant with rituximab and conversionto mTOR inhibitor. Colomb Med (Cali). 2016 Dec30;47(4):196-202.

14. Ashrafi F, Shahidi S, Mehrzad V, MortazaviM, Hosseini SF. Survival of Post-TransplantLymphoproliferative Disorder after KidneyTransplantation in Patients under RapamycinTreatment. Int J Hematol Oncol Stem Cell Res. 2021Oct 1;15(4):239-248.

15. Klintmalm GB, Saab S, Hong JC, Nashan B. Therole of mammalian target of rapamycin inhibitors inthe management of post-transplant malignancy. ClinTransplant. 2014 Jun;28(6):635-48.

16. Witzig TE, Reeder CB, LaPlant BR, GuptaM, Johnston PB, Micallef IN, et al. A phase IItrial of the oral mTOR inhibitor everolimus inrelapsed aggressive lymphoma. Leukemia. 2011Feb;25(2):341-7.

17. Xu W, Berning P, Erdmann T, Grau M, BettazováN, Zapukhlyak M, et al. mTOR inhibition amplifiesthe anti-lymphoma effect of PI3Kβ/δ blockage indiffuse large B-cell lymphoma. Leukemia. 2023Jan;37(1):178-189.